LB Pharmaceuticals Inc (LBRX)

NASDAQ: LBRX · Real-Time Price · USD
15.65
-0.92 (-5.55%)
Oct 29, 2025, 4:00 PM EDT - Market closed
-5.55%
Market Cap351.23M
Revenue (ttm)n/a
Net Income (ttm)-29.43M
Shares Out 22.44M
EPS (ttm)-116.88
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume53,643
Open16.42
Previous Close16.57
Day's Range15.46 - 16.90
52-Week Range13.36 - 20.25
Betan/a
AnalystsStrong Buy
Price Target46.33 (+196.04%)
Earnings DateNov 21, 2025

About LBRX

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 1 clinical trial for the treatment of bipolar I depression; and in pr clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 11, 2025
Employees 16
Stock Exchange NASDAQ
Ticker Symbol LBRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for LBRX stock is "Strong Buy." The 12-month stock price target is $46.33, which is an increase of 196.04% from the latest price.

Price Target
$46.33
(196.04% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs

NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the appointment of James Rawls, Pharm.D., as Senior Vice Presi...

15 days ago - GlobeNewsWire

LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that three posters featuring new and previously reported analy...

23 days ago - GlobeNewsWire

LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the appointments of William Kane and Rekha Hemrajani to its B...

4 weeks ago - GlobeNewsWire

LB Pharma valued at $382 million as shares jump in New York debut

LB Pharmaceuticals' shares rose 27% in their Nasdaq debut on Thursday, giving the biotech firm a valuation of $381.9 million and opening the door for companies looking to tap the public markets before...

6 weeks ago - Reuters

LB Pharmaceuticals raises $285 million in US IPO

LB Pharmaceuticals raised $285 million in its U.S. initial public offering, the biotech firm said on Wednesday, marking the first sizable biotech IPO since February.

7 weeks ago - Reuters

LB Pharmaceuticals Announces Pricing of its Upsized Initial Public Offering

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals”) today announced the pricing of its upsized initial public offering of 19,000,000 shares of its common stock a...

7 weeks ago - GlobeNewsWire

LB Pharmaceuticals eyes $322 million valuation in biotech IPO amid sector drought

Cash-strapped drug developer LB Pharmaceuticals said on Monday it was aiming for a valuation of up to $321.6 million in its New York initial public offering, potentially setting up the first sizable U...

7 weeks ago - Reuters

LB Pharmaceuticals Launches $100 Million IPO Effort

LB Pharmaceuticals Inc. is preparing a $100 million IPO to fund Phase 3 trials for its schizophrenia drug, LB-102, after positive Phase 2 results. The company targets a large, growing schizophrenia dr...

2 months ago - Seeking Alpha

Neuropsychiatry biotech LB Pharmaceuticals files for a $100 million IPO

LB Pharmaceuticals, a Phase 3 biotech developing therapies for neuropsychiatric diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

2 months ago - Renaissance Capital

LB Pharmaceuticals IPO Registration Document (S-1)

LB Pharmaceuticals has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC